Found 15 matching trials
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer PHASE2 The study is being conducted to to explore the reasonable dosage and evalua...
Show More Location
Multiple Locations
Learn More & Join Trial
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors PHASE1 The study is being conducted to explore the reasonable dosage and evaluate ...
Show More Location
Hunan Provincial Cancer Hospital
Learn More & Join Trial
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer PHASE1 This study is a phase Ib/II study to evaluate the efficacy, safety and tole...
Show More Location
Sun Yat-Sen University Cancer Center
Learn More & Join Trial
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) PHASE2 The study is being conducted to to explore the reasonable dosage and evalua...
Show More Location
MD Anderson Cancer Hospital
Learn More & Join Trial
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma PHASE2 The study is being conducted to to explore the reasonable dosage and evalua...
Show More Location
Beijing Cancer Hospital
Learn More & Join Trial
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC PHASE2 The study is being conducted to to explore the reasonable dosage and evalua...
Show More Location
Shanghai Pulmonary Hospital
Learn More & Join Trial
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer PHASE2 The study is being conducted to to explore the reasonable dosage and evalua...
Show More Location
Beijing Cancer Hospital
Learn More & Join Trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors PHASE2 The study is being conducted to explore the reasonable dosage and evaluate ...
Show More Location
Shandong Cancer Hospital
Learn More & Join Trial
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors PHASE1 This study is an open-label first-in-human phase I clinical study to evalua...
Show More Status
Enrolling By Invitation
Location
Stanford University
Learn More & Join Trial
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer. PHASE2 The study is being conducted to explore the reasonable dosage and evaluate ...
Show More Location
Harbin Medical University Affiliated Cancer Hospital
Learn More & Join Trial